On January 21, the WHO 130th WHO Executive Board (EB) adopted a resolution for agenda item 6.13 "substandard/spurious/falsely-labelled/falsified/counterfeit medical products” [SFFC]. The resolution is intended to address the growing prevalence of and the health risks associated with “deliberately and fraudulently mislabelled” pharmaceuticals.
Access to information is generally important in a free and democratic society. It’s particularly important in the context of regulating drugs, medical devices, and other products. In Merck Frosst Canada Ltd. v. Canada (Health), the Supreme Court of Canada affirmed Health Canada’s decision to disclose certain information about Merck’s asthma medication Singulair®. The Court rejected […]
Lena Vartanian is a JD candidate at Osgoode Hall Law School and is enrolled in Professor Mgbeoji’s Patents class in Fall 2011. As part of the course requirements, students are asked to write a blog on a topic of their choice. On October 11, 2011, Apotex Inc. announced its latest successful patent challenge, resulting in […]
Dr. Ron Bouchard is an Associate Professor in the Faculties of Law and of Medicine at the University of Manitoba, a CIHR New Investigator and an IP Osgoode Research Affiliate. In Part 1, we learned that it is both possible and valuable to import empirical scientific methods typically used in the hard sciences to the […]
Ivy Tsui is a JD candidate at Osgoode Hall Law School and is enrolled in Professor Mgbeoji’s Patents class in Fall 2011. As part of the course requirements, students are asked to write a blog on a topic of their choice. In the genomic era, the flood of computationally predicted genes has introduced a new […]
Dr. Ron Bouchard is an Associate Professor in the Faculties of Law and of Medicine at the University of Manitoba, a CIHR New Investigator and an IP Osgoode Research Affiliate. An earlier article on IP Osgoode by Chaubal gives admirable service to the issue of patent valuation, which presents to a wide audience as a […]
A. Samuel Oddi is a professor of Intellectual Property at the University of Akron School of Law. In prior articles,[3] I have tried to point out that developing countries, and particularly the least developed countries (LDCs), are not the intended or even incidental beneficiaries of the intellectual property system--particularly its internationalization under TRIPS. I have primarily […]
Dan Whalen is a JD candidate at Osgoode Hall Law School. On August 17, 2011, Health Canada released proposed revisions to its Guidance Document: Patented Medicines (Notice of Compliance) Regulations for stakeholder consultation. In a welcome effort to bring greater efficiency to the drug approval process, the proposed revisions exempt administrative drug submissions from compliance […]
Kalen Lumsden is a JD candidate at Osgoode Hall Law School. On June 1, 2011, Pfizer, manufacturer of the erectile dysfunction drug Viagra, filed suit against rival Watson Pharmaceuticals to frustrate its attempts to produce a generic version of the drug. The next day Watson confirmed that it had applied to the US Food and […]
Dan Whalen is a JD candidate at Osgoode Hall Law School. The Canada Gazette published amendments to the Patented Medicines (Notice of Compliance) Regulations, which include much-anticipated provisions for Extraordinary Use New Drugs (EUNDS). This addition is aimed at empowering Canada to prevent and respond to the threat of disease outbreaks and align its approach […]